Apart from the efficacy data, Pfizer has revealed key details pertaining to instances of severe cases. Pfizer has said that during the trial, 10 severe cases of Covid-19 came to the notice. Out of the 10, one case occurred in the two-dose mRNA vaccine group and nine cases were detected in the placebo group.
Here are key highlights of Pfizer-BioNTech vaccine phase 3 study
Pfizer-BioNTech’s BNT162b2 has proven to be 95 per cent effective against Coronavirus commencing 28 days after the first dose. A total of 170 Coronavirus confirmed cases were monitored — 162 were in the placebo group and eight in the vaccine group.
Pfizer-BioNTech’s BNT162b2 Covid-19 vaccine showed consistent efficacy across gender, age, ethnicity demographics and race. In a positive sign, Pfizer-BioNTech’s Coronavirus vaccine had an efficacy of 94 per cent in the age group of 65 years and more.
Regarding the side-effects, Pfizer-BioNTech has also released data regarding reactogenicity. Reactogenicity denotes the ability to produce common adverse reactions on participants during phase 3 human trials. The data shows that severe adverse effect like fatigue was noticeable in 2 per cent, fatigue was visible at 3.8 per cent and headache at 2.0 per cent.
Pfizer-BioNTech’s BNT162b2 Covid-19 vaccine was found to be well tolerated as more than 43,000 participants enrolled for a human trial.
Pfizer Chairman and CEO Dr. Albert Bourla termed efficacy results as a pivotal step in the company’s historic eight-month journey of developing the elusive Coronavirus vaccine. He said that Pfizer-BioNTech’s BNT162b2 Covid-19 vaccine has the capacity to end the prevalent Coronavirus pandemic.
Pfizer-BioNTech started the Phase 3 clinical trial of BNT162b2 on July 27. As many as 43,661 participants were enrolled. Out of the total, 41,135 have received a second dose of BNT162b2 Covid-19 vaccine candidate as of November 13, 2020.